Uncategorized
Ophthotech, Novartis enter into ex-US licensing and commercialization agreement
Ophthotech Corporation has entered into an ex-U.S. licensing and commercialization agreement with Novartis Pharmaceuticals for Fovista, an anti-PDGF in development for the treatment of wet age-related macular degeneration, according to a press release.This agreement entitles Novartis to commercialize Fovista in markets outside of the United States. Ophthotech will continue to commercialize Fovista in the United States and lead the Fovista phase 3 wet AMD clinical program.